Will This Price Target Increase Help Mallinckrodt (MNK) Stock Today?

Story updated at 9:55 a.m. to reflect market activity.

NEW YORK (TheStreet) -- UBS raised its price target for Mallinckrodt (MNK) to $94 from $91 Monday, reiterating its "buy" rating for the generic drug producer.

Mallinckrodt gained 1.9% to $80.39 in morning trading.

The firm also raised its EPS estimates for the company. UBS analyst Marc Goodman cited the price increase of Ofirmex as a reason for the price target increase.

"We conservatively assume 50% of the 140% price increase would flow through, but the flow through could be higher," Goodman wrote. "We also assume the substantial price increase would negatively impact volume growth, so we slowed our growth rate assumptions with a substantially greater impact initially, which tapers off in later quarters. The net effect is an increase in FY2015-2016 revenues in the $60-70M per year range, which increases our pro-forma EPS to $6.15 and $7.25 (from $5.85 and $7.00), respectively. If our assumptions prove conservative, we could see upside to our numbers."

Must read: Warren Buffett's 10 Favorite Growth Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

MNK Chart

MNK data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

The Stock Market Gets Smashed -- Here Are Some Terrible Performers

Top Ranking Democrat McCaskill Expands Probe into Opioid Crisis

Earnings Are Back With a Vengeance: Cramer's 'Mad Money' Recap (Monday 7/24/17)